Conexeu Sciences Inc. (CNXU) Key Metrics
CNXU valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $86.3M
- Enterprise value
- $115.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 20.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
CNXU key metrics, FY2024–FY2025
Fiscal year ended October 31, 2025 · U.S. dollarsCNXU returns How much profit the business earns on the capital it uses.
CNXU per-share figures Results divided by the shares outstanding at year-end.
CNXU financial health Debt, liquidity and how easily interest is covered.
CNXU returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CNXU debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CNXU key metrics
FY2024–FY2025| FY2025 | FY2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.00 | $0.00 |
| Earnings per share | −$0.19 | −$0.02 |
| Operating cash flow per share | −$0.08 | −$0.01 |
| Free cash flow per share | −$0.08 | −$0.01 |
| Cash per share | $0.23 | $0.02 |
| Book value per share | $0.35 | $0.00 |
| Tangible book value per share | $0.34 | −$0.00 |
| Capex per share | $0.00 | $0.00 |
| Debt per share | — | $0.00 |
| Shares outstanding | 20.9M | 20.9M |
| Change in shares outstanding | 0.0% | — |
| Returns & profitability | ||
| Return on equity (ROE) | −105.4% | −496.9% |
| Return on invested capital (ROIC) | −258.2% | — |
| Return on assets (ROA) | −95.4% | −88.4% |
| Return on tangible assets | −52.2% | −135.9% |
| Financial health | ||
| Total debt | — | $98,117 |
| Cash & short-term investments | $4.8M | $314,616 |
| Net debt | −$4.8M | −$216,499 |
| Debt / equity | — | 1.03 |
| Debt / assets | — | 0.18 |
| Current ratio | 22.20 | 1.02 |
| Quick ratio | 22.20 | 1.02 |
| Interest coverage | -799.8 | -39.0 |
| Working capital | $7.1M | $6,378 |
| Invested capital | $2.5M | −$121,535 |
| Tangible asset value | $7.2M | −$91,739 |
| Net current asset value | $7.1M | −$91,739 |
| Graham net-net per share | $0.21 | −$0.01 |
| Capital allocation | ||
| Capex / depreciation | 1.08 | — |
| Efficiency | ||
| Asset turnover | 0.00 | 0.00 |
| Average payables | $287,660 | $319,024 |
| Intangibles / total assets | 2.3% | 35.0% |
Computed from CNXU's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CNXU valuation and financial ratios
Conexeu Sciences earned a return on equity of −105.4% and a return on invested capital of −258.2% in fiscal 2025.
See the CNXU income statement, the CNXU chart for price history, or the CNXU stock overview for the latest quote and news.
CNXU key metrics FAQ
What is Conexeu Sciences's return on equity?
Conexeu Sciences's return on equity (ROE) was −105.4% in fiscal 2025: net income of -$3.9 million on average shareholders' equity of $3.7 million.
What is Conexeu Sciences's ROIC?
Conexeu Sciences's return on invested capital was −258.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Conexeu Sciences's current ratio?
Conexeu Sciences's current ratio was 22.20 at the end of fiscal 2025: current assets were 22.20 times current liabilities.